ATB-330

ATB-330
Product Description

[ALK5 inhibitor / Small Molecule / Develop for IPF and Fibrosis) - Complete to derivate the lead compound 1. Confirm the highest ALK5 selectivity with superior efficacy and PK profile through in-vivo tests compared to competitors (small molecule new drugs) 2. For IPF treatment, develop as inhalation therapy to avoid systemic exposure and minimize possible toxicities - ALK5 inhibitor projects are dropped due to the side effects such as hepatotoxicity, skin toxicity, and cardiotoxicity through systemic circulation in clinical trials 3. Confirm the superior efficacy compared to the standard therapy of IPF through in-vivo tests

Read more Show less

Autotelic Bio

  • Country/Region:
    Korea, Republic Of
  • On CPHI since:
    2021
  • Employees:
    25 - 49
Company types
Manufacturer/Innovator
Pharmaceutical company
Primary activities
Pharmaceutical Company (innovator finished products)
View company profile
Categories
more categories Show less

Autotelic Bio

  • Country/Region:
    Korea, Republic Of
  • On CPHI since:
    2021
  • Employees:
    25 - 49
Company types
Manufacturer/Innovator
Pharmaceutical company
Primary activities
Pharmaceutical Company (innovator finished products)
View company profile

More Products from Autotelic Bio (5)

  • ATB-101

    Product ATB-101

    ATB-101 is the world’s first fixed-dose combination of olmesartan and dapagliflozin, designed for patients with hypertension and type 2 diabetes. A Phase 3 study has been completed in Korea, with regulatory approval expected in Q1 2027. U.S. development is progressing through the FDA 505(b)(2) pathway, wit...
  • ATB-301

    Product ATB-301

    [TGF-β2 Targeting ASO (TASO) + IL-2 Combination therapy] - Phase Ib 1. Confirm the potential of TGF-β2 as a biomarker in human blood and tumor tissues from the efficacy result of Phase Ib clinical trial on cancer patients 2. Confirm the suppression of IL-2's side effect in combination therapy which is c...
  • ATB-320

    Product ATB-320

    [Immune Targeting Dual MOA anti-cancer agent] - Pre-clinical toxicology, TK, and safety pharmacology studies are ongoing and expect to be approved for Phase I IND by US FDA in 1st quarter of 2023 1. Confirmation of the synergistic effect of combination therapy with PD-1 & cytotoxic drugs in pre-clinical ...
  • ATB-720

    Product ATB-720

    ATB-720 is a first-in-class topical antisense oligonucleotide (ASO) candidate for atopic dermatitis. Designed to deliver targeted activity directly to the skin while minimizing systemic exposure, ATB-720 has demonstrated compelling preclinical efficacy and offers a novel, non-steroidal treatment approach.
  • ATB-810

    Product ATB-810

    ATB-810 is a first-in-class antisense oligonucleotide (ASO) candidate for the treatment of ALS and progressive multiple sclerosis. Powered by Autotelic Bio’s proprietary C-Duplex™ technology, it is designed to achieve broad brain distribution and improved tolerability, with compelling efficacy demonstrated...